➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Johnson and Johnson
Mallinckrodt
Harvard Business School

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMBRUVICA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

505(b)(2) Clinical Trials for Imbruvica

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02841150 ↗ Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules Completed Janssen Research & Development, LLC Phase 1 2016-06-01 The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.
New Formulation NCT02877225 ↗ Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule Recruiting Janssen Research & Development, LLC Phase 1 2016-08-01 The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Imbruvica

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01779791 ↗ A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma Completed Pharmacyclics LLC. Phase 2 2013-04-01 The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01779791 ↗ A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma Completed Janssen Research & Development, LLC Phase 2 2013-04-01 The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
NCT01829568 ↗ Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Active, not recruiting Celgene Corporation Phase 1 2013-06-01 This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
NCT01829568 ↗ Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1 2013-06-01 This phase I clinical trial studies the side effects and best dose of lenalidomide and ibrutinib when given together with rituximab in treating patients with previously untreated stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib together with rituximab may work well in treating follicular lymphoma.
NCT01841723 ↗ Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Recruiting National Cancer Institute (NCI) Phase 2 2013-04-01 This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imbruvica

Condition Name

Condition Name for Imbruvica
Intervention Trials
Chronic Lymphocytic Leukemia 29
Mantle Cell Lymphoma 12
Small Lymphocytic Lymphoma 12
Refractory Chronic Lymphocytic Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imbruvica
Intervention Trials
Lymphoma 62
Leukemia, Lymphoid 50
Leukemia, Lymphocytic, Chronic, B-Cell 49
Leukemia 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imbruvica

Trials by Country

Trials by Country for Imbruvica
Location Trials
United States 320
Spain 18
Canada 10
Japan 9
Australia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imbruvica
Location Trials
Texas 29
Ohio 23
California 21
Massachusetts 18
New York 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imbruvica

Clinical Trial Phase

Clinical Trial Phase for Imbruvica
Clinical Trial Phase Trials
Phase 4 1
Phase 3 14
Phase 2 65
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imbruvica
Clinical Trial Phase Trials
Recruiting 71
Not yet recruiting 50
Active, not recruiting 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imbruvica

Sponsor Name

Sponsor Name for Imbruvica
Sponsor Trials
National Cancer Institute (NCI) 44
Pharmacyclics LLC. 22
M.D. Anderson Cancer Center 19
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imbruvica
Sponsor Trials
Other 105
Industry 94
NIH 44
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Colorcon
Mallinckrodt
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.